PT2143420E - Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry - Google Patents

Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry Download PDF

Info

Publication number
PT2143420E
PT2143420E PT90117615T PT09011761T PT2143420E PT 2143420 E PT2143420 E PT 2143420E PT 90117615 T PT90117615 T PT 90117615T PT 09011761 T PT09011761 T PT 09011761T PT 2143420 E PT2143420 E PT 2143420E
Authority
PT
Portugal
Prior art keywords
galactosidase
treatment
mutant
formulation
fabry disease
Prior art date
Application number
PT90117615T
Other languages
English (en)
Inventor
Jian-Qiang Fan
Satoshi Ishii
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of PT2143420E publication Critical patent/PT2143420E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT90117615T 1998-06-01 1999-05-28 Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry PT2143420E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/087,804 US6274597B1 (en) 1998-06-01 1998-06-01 Method of enhancing lysosomal α-Galactosidase A

Publications (1)

Publication Number Publication Date
PT2143420E true PT2143420E (pt) 2014-09-30

Family

ID=22207362

Family Applications (2)

Application Number Title Priority Date Filing Date
PT90117615T PT2143420E (pt) 1998-06-01 1999-05-28 Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry
PT99925611T PT1083899E (pt) 1998-06-01 1999-05-28 Derivados de 1-desoxi-galactonojirimicina e respectiva utilização no tratamento de doenças de acumulação lisossomal, por intensificação da alfa-galactosidase a lisossomal

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT99925611T PT1083899E (pt) 1998-06-01 1999-05-28 Derivados de 1-desoxi-galactonojirimicina e respectiva utilização no tratamento de doenças de acumulação lisossomal, por intensificação da alfa-galactosidase a lisossomal

Country Status (12)

Country Link
US (16) US6274597B1 (pt)
EP (2) EP1083899B1 (pt)
JP (2) JP4602548B2 (pt)
AT (1) ATE442851T1 (pt)
AU (1) AU4186199A (pt)
CA (1) CA2333965C (pt)
CY (2) CY1112845T1 (pt)
DE (1) DE69941429D1 (pt)
DK (2) DK1083899T3 (pt)
ES (2) ES2507515T3 (pt)
PT (2) PT2143420E (pt)
WO (1) WO1999062517A1 (pt)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
US6849257B2 (en) 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
WO2003022797A1 (fr) * 2001-09-07 2003-03-20 Seikagaku Corporation Derives de carba-sucres amine et traitements du trouble du metabolisme des glycolipides les contenant en tant qu'ingredient actif
US7842470B2 (en) * 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
WO2004004740A1 (en) * 2002-07-05 2004-01-15 King Roderick Frederick Gerard Aqueous formulation comprising digestible saccharides to reduce the tendency to cardiovascular disease in a subject
WO2004037373A2 (en) * 2002-10-21 2004-05-06 The Scripps Research Institute CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE
US20040180419A1 (en) * 2003-01-31 2004-09-16 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
CA2526173A1 (en) * 2003-05-22 2004-12-02 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2004289327A1 (en) * 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CA2507348C (en) * 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
US20090239807A1 (en) * 2004-05-24 2009-09-24 Mia Horowitz Methods and kits for diagnosing and/or assessing severity and treating gaucher disease
CA2568150A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
FR2873377B1 (fr) * 2004-07-23 2006-10-13 Sanofi Synthelabo Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
US9181184B2 (en) 2005-05-17 2015-11-10 Amicus Therapeutics, Inc. Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
KR20080033242A (ko) * 2005-06-08 2008-04-16 아미쿠스 세라퓨틱스, 인코포레이티드 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
AU2015230773B2 (en) * 2006-05-16 2017-09-28 Amicus Therapeutics Inc. Assays for diagnosing and evaluating treatment options for fabry disease
SI2533050T1 (sl) * 2006-05-16 2014-07-31 Amicus Therapeutics, Inc. MoĹľnosti zdravljenja Fabrijeve bolezni
AU2013205532B8 (en) * 2006-05-16 2015-07-16 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
DE602007013648D1 (de) * 2006-05-24 2011-05-19 Amicus Therapeutics Inc Tartratsalz aus Isofagomin und Verwendungsverfahren dafür
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
KR101402554B1 (ko) 2006-06-23 2014-06-19 아미쿠스 세라퓨틱스, 인코포레이티드 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
WO2008088581A2 (en) * 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections
US20100144008A1 (en) * 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
EP2155197A4 (en) * 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
EP2142197A4 (en) * 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
MX2009011055A (es) * 2007-04-13 2010-01-13 Amicus Therapeutics Inc Tratamiento de la enfermedad de gaucher con chaperonas farmacologicas especificas y supervision del tratamiento utilizando marcadores sustitutos.
MX2009011022A (es) * 2007-04-13 2010-01-13 Amicus Therapeutics Inc Uso de sustratos como chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9056101B2 (en) * 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2152265B1 (en) 2007-05-22 2014-06-04 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
WO2009049421A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
EP2252288A1 (en) * 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
PT2252313E (pt) 2008-02-12 2015-08-26 Amicus Therapeutics Inc Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
ES2963910T3 (es) 2008-06-26 2024-04-03 Zevra Denmark As Uso de Hsp70 como regulador de la actividad enzimática
US8321148B2 (en) * 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US20100119502A1 (en) * 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
EP2410989A2 (en) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
GB0906159D0 (en) * 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
AU2010254092B2 (en) * 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US9206457B2 (en) * 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US20110112041A1 (en) * 2009-10-01 2011-05-12 Baylor Research Institute Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease
ES2549504T3 (es) * 2009-10-19 2015-10-28 Amicus Therapeutics, Inc. Método para el tratamiento de la enfermedad de Alzheimer utilizando chaperonas farmacológicas para aumentar la actividad de gangliosidasas
DK2490532T3 (en) 2009-10-19 2017-02-27 Amicus Therapeutics Inc Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
CN105193802A (zh) * 2009-10-19 2015-12-30 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的新颖组合物
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
ES2555555T3 (es) * 2010-01-28 2016-01-04 Raptor Pharmaceuticals Inc. Conjugados de péptido de proteína asociada al receptor inhibidor de fucosidasa y su uso en el tratamiento de tumores hepáticos
US20130040990A1 (en) * 2010-02-02 2013-02-14 The Chancellor, Masters And Scholars Of The University Of Oxford SYNTHESIS OF DGJNAc FROM D-GLUCURONOLACTONE AND USE TO INHIBIT ALPHA-N-ACETYLGALACTOSAMINIDASES
EP2646044B1 (en) 2010-11-30 2019-08-28 Orphazyme A/S Methods for increasing intracellular activity of hsp70
CN103974619B (zh) * 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
US20140350049A1 (en) 2011-11-29 2014-11-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of darier disease
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
EP2854910B1 (en) 2012-06-01 2020-04-15 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
EP2943200B9 (en) 2013-01-09 2020-07-22 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
RS65066B1 (sr) 2014-09-30 2024-02-29 Amicus Therapeutics Inc Visoko potentna kisela alfa-glukozidaza sa pojačanim ugljenim hidratima
CA3162308A1 (en) 2015-02-05 2016-08-11 Cardiovalve Ltd. Prosthetic valve with axially-sliding frames
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2016381832B2 (en) 2015-12-30 2024-01-25 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
JP7098529B2 (ja) * 2016-03-22 2022-07-11 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR20240001291A (ko) 2016-03-30 2024-01-03 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
HUE052158T2 (hu) 2016-04-29 2021-04-28 Orphazyme As Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez
US20190183869A1 (en) 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
EP4062915A1 (en) 2017-05-30 2022-09-28 Amicus Therapeutics, Inc. Migalastat bound to alpha galactosidase a
MX2019014410A (es) 2017-05-30 2020-02-10 Amicus Therapeutics Inc Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
EP3630725A1 (en) 2017-06-01 2020-04-08 Idorsia Pharmaceuticals Ltd Crystalline form of n-butyldeoxygalactonojirimycin
JP7066157B2 (ja) * 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
PL3675853T3 (pl) 2017-08-28 2022-12-27 Amicus Therapeutics, Inc. Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego
US20200206323A1 (en) * 2017-09-08 2020-07-02 The Nemours Foundation An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases
US11304806B2 (en) 2017-09-19 2022-04-19 Cardiovalve Ltd. Prosthetic valve with atrial tissue anchors having variable flexibility and ventricular tissue anchors having constant flexibility
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
HRP20240025T1 (hr) 2018-02-06 2024-03-29 Amicus Therapeutics, Inc. Liječenje bolesnika s klasičnom fabrijevom bolešću migalastatom
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
KR20240017128A (ko) 2018-08-20 2024-02-06 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
TW202042812A (zh) 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
KR20220019796A (ko) 2019-06-11 2022-02-17 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 환자에서 파브리 질병을 치료하는 방법
AU2020327019A1 (en) 2019-08-07 2022-03-03 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
WO2021067324A1 (en) 2019-10-04 2021-04-08 Academia Sinica Methods of treating pompe disease
US11666574B2 (en) * 2019-11-27 2023-06-06 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
CA3167476A1 (en) * 2020-02-10 2021-08-19 Nina SKUBAN Methods of treating fabry disease
TW202146020A (zh) 2020-03-06 2021-12-16 美商阿米庫斯醫療股份有限公司 治療在ＧＬＡ基因中具有突變的患者的Ｆａｂｒｙ氏病之方法
JP2024500632A (ja) 2020-11-19 2024-01-10 ゼブラ デンマーク エー／エス アリモクロモルクエン酸塩及びその中間体の調製プロセス
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
KR20240034203A (ko) 2021-07-12 2024-03-13 아미쿠스 세라퓨틱스, 인코포레이티드 소아청소년 환자에서 파브리병을 치료하는 방법
WO2023060233A1 (en) 2021-10-08 2023-04-13 Amicus Therapeutics, Inc. Biomarkers for lysosomal storage diseases
US20240197706A1 (en) 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS61280472A (ja) 1985-06-05 1986-12-11 Shionogi & Co Ltd β−ガラクトシダ−ゼ阻害物質ガラクトスタチン類およびその製造方法
WO1987003903A1 (en) 1985-12-23 1987-07-02 Fred Hutchinson Cancer Research Center Regulating retroviral replication, infection, and pathogenesis
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US5250545A (en) 1988-02-12 1993-10-05 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitor methods
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5504078A (en) 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
CA2086413A1 (en) 1990-06-29 1991-12-30 Yohji Ezure Piperidine derivatives
US5276120A (en) 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6291657B1 (en) * 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
JPH0748398A (ja) 1993-08-03 1995-02-21 Nippon Oil Co Ltd 変性蛋白質の再生方法及び変性蛋白質再生剤
US5691306A (en) 1993-08-26 1997-11-25 National Research Council Of Canada Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production
DK0739205T3 (da) 1994-01-13 2000-05-01 Searle & Co Anvendelse af N-alkylderivater af 1,5-didesoxy-1,5-imino-D-glucitol til behandling af hepatitis-B-virusinfektioner
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
AU732552B2 (en) 1996-07-15 2001-04-26 Genzyme Corporation Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
KR100547402B1 (ko) 1996-09-13 2006-02-01 트랜스케리오틱 쎄러피스, 인코포레이티드 α-갈락토시다아제 Ａ 결핍을 치료하는 방법
GB9700233D0 (en) 1997-01-08 1997-02-26 Univ London Use of glycosidase inhibitors
US6210666B1 (en) * 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
ES2216327T3 (es) 1997-11-10 2004-10-16 G.D. SEARLE &amp; CO. Uso de iminoazucares alquilados para tratar la resistencia a multiples a farmacos.
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
AU2590099A (en) 1998-02-09 1999-08-23 William J. Netzer Protein folding inhibitors
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2000029556A2 (en) 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
EA003326B1 (ru) 1998-12-02 2003-04-24 Пфайзер Продактс Инк. Способ лечения рака
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
JP2000219632A (ja) 1999-01-28 2000-08-08 Toyotama Koryo Kk カロリー軽減剤
WO2000056334A1 (en) 1999-03-19 2000-09-28 The Trustees Of Boston College Use of imino sugars for anti-tumor therapy
BR0009840A (pt) 1999-04-19 2002-01-08 Schering Corp Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6476194B1 (en) 1999-06-29 2002-11-05 National Research Council Of Canada Method for folding unfolded proteins
CA2378776A1 (en) 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
AU1840101A (en) 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
AU7712000A (en) 1999-09-24 2001-04-24 Johns Hopkins University School Of Medicine, The Methods for identifying an agent that corrects defective protein folding
WO2001052830A2 (en) 2000-01-20 2001-07-26 Washington University METHODS TO TREAT α-1-ANTITRYPSIN DEFICIENCY
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020115619A1 (en) 2000-10-04 2002-08-22 Rubenstein Ronald C. Compositions and methods for treatment of cystic fibrosis
JP2002190202A (ja) 2000-10-12 2002-07-05 Koito Mfg Co Ltd ヘッドランプ
JP3589449B2 (ja) 2001-02-26 2004-11-17 株式会社ユニレック 静電容量センサ、管内流動判断装置、管内流動制御装置
JP4802548B2 (ja) * 2005-04-28 2011-10-26 シンフォニアテクノロジー株式会社 Ｉｃチップ実装体の製造装置
US7174582B1 (en) 2005-08-17 2007-02-13 Kevin J Leary Crib mattress bouncer
JP2011514332A (ja) 2008-02-14 2011-05-06 シグナム バイオサイエンシーズ， インコーポレイテッド イソプレニル−ｓ−システイニルメチルトランスフェラーゼの阻害のためのアセチルミミック化合物
AU2009314165B2 (en) 2008-11-11 2014-05-15 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
JP2012515721A (ja) 2009-01-20 2012-07-12 シグナム バイオサイエンシーズ， インコーポレイテッド 抗炎症性複合体

Also Published As

Publication number Publication date
US6274597B1 (en) 2001-08-14
ATE442851T1 (de) 2009-10-15
DE69941429D1 (de) 2009-10-29
US20140206718A1 (en) 2014-07-24
US9265780B2 (en) 2016-02-23
EP2143420A1 (en) 2010-01-13
WO1999062517A1 (en) 1999-12-09
JP2010270146A (ja) 2010-12-02
EP1083899B1 (en) 2009-09-16
US6916829B2 (en) 2005-07-12
US20020198225A1 (en) 2002-12-26
US8436018B2 (en) 2013-05-07
US7514453B2 (en) 2009-04-07
EP2143420B1 (en) 2014-06-25
DK2143420T3 (da) 2014-10-06
US8841322B2 (en) 2014-09-23
DK1083899T3 (da) 2010-01-25
JP4602548B2 (ja) 2010-12-22
US20040242539A1 (en) 2004-12-02
US20070021381A1 (en) 2007-01-25
US20020156100A1 (en) 2002-10-24
ES2333561T3 (es) 2010-02-23
US20050113415A1 (en) 2005-05-26
US20160346262A1 (en) 2016-12-01
CY1115583T1 (el) 2017-01-04
US20020035072A1 (en) 2002-03-21
JP2003528799A (ja) 2003-09-30
US20110076765A1 (en) 2011-03-31
US20060100241A1 (en) 2006-05-11
AU4186199A (en) 1999-12-20
US20140051725A1 (en) 2014-02-20
US6599919B2 (en) 2003-07-29
US7141582B2 (en) 2006-11-28
US6583158B1 (en) 2003-06-24
CY1112845T1 (el) 2016-02-10
US20150258129A1 (en) 2015-09-17
JP5528941B2 (ja) 2014-06-25
CA2333965C (en) 2011-03-22
US8633221B2 (en) 2014-01-21
ES2507515T3 (es) 2014-10-15
US20030119874A1 (en) 2003-06-26
PT1083899E (pt) 2009-12-18
US6774135B2 (en) 2004-08-10
CA2333965A1 (en) 1999-12-09
EP1083899A4 (en) 2004-11-03
US7622485B2 (en) 2009-11-24
US7812033B2 (en) 2010-10-12
US20100137229A1 (en) 2010-06-03
US6589964B2 (en) 2003-07-08
EP1083899A1 (en) 2001-03-21

Similar Documents

Publication Publication Date Title
PT2143420E (pt) Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
IL177228A0 (en) Use of a vector for the manufacture of a medicament for treating gaucher disease
WO1998011206A3 (en) THERAPY FOR α-GALACTOSIDASE A DEFICIENCY
NO308854B1 (no) Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav
PL319833A1 (en) Compounds and composition for carrying active media
CA2263561A1 (en) Thienopyrimidines
TW225532B (pt)
GR3032744T3 (en) Surface expression of enzyme in gene directed prodrug therapy
EP1634605A3 (en) treatment of dyslipidemia in a patient having type 2 diabetes
PL336233A1 (en) Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity
AU2005188A (en) Pharmaceutical composition for intranasal administration comprising gh-releasing hormone, a cholinergic agonist and in case a bile salt
GR3036287T3 (en) Substituted imidazo(4,5-b)pyridines and benzimidazoles as angiotensin II antagonistes.
WO1991015466A3 (en) Aminopolycarboxylic acid chelating agents
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
HUT75861A (en) New peptide active substance and production thereof
YU58900A (sh) Lečenje paničnih napada
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
AU1621788A (en) Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease
IE880515L (en) Therapeutic agent comprising a phthalazine derivative
AU5870298A (en) 1,4-dihydropyridin derivatives and their use in therapy
AU3634795A (en) Clotrimazole metabolites in the treatment of sickle cell disease
PL314933A1 (en) Prophylatic and therapeutic agent for mouth care, in particular for preventing paradontium diseases
CS648987A1 (en) Agent for epidermis cultivation,attention and protection.
UA32157A (uk) Спосіб лікування діабетичної ретинопатії